...
首页> 外文期刊>International Journal of Pharmaceutics >In-situ forming chitosan implant-loaded with raloxifene hydrochloride and bioactive glass nanoparticles for treatment of bone injuries: Formulation and biological evaluation in animal model
【24h】

In-situ forming chitosan implant-loaded with raloxifene hydrochloride and bioactive glass nanoparticles for treatment of bone injuries: Formulation and biological evaluation in animal model

机译:原位形成壳聚糖植入氯氰酸盐酸盐酸盐和生物活性玻璃纳米粒子,用于治疗骨损伤:动物模型中的制剂和生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

In-situ forming implants receive great attention for repairing serious bone injuries. The aim of the present study was to prepare novel chitosan in-situ forming implants (CIFI) loaded with bioactive glass nanoparticles and/or raloxifene hydrochloride (RLX). Incorporating raloxifene hydrochloride (RLX) as a selective estrogen receptor modulator was essential to make use of its anti-resorptive properties. The prepared formulae were tested for their in-vitro gelation time, drug release, injectability, rheological properties, erosion rate and morphological properties. Results revealed that the formulation composed of 1% (w/v) chitosan with 2% (w/v) NaHCO3 and 1% (w/v) bioactive glass nanoparticles (CIFI-BG) possessed the most sustained drug release profile which extended over four months with low burst release effect compared to the same formulation lacking bioactive glass nanoparticles (CIFI). Selected formulations were tested for their ability to enhance bone regeneration in induced puncture in rate tibia. Results declared that these formulations were able to enhance bone regeneration after 12 weeks in comparison to the untreated tibial punctures and that containing bioactive glass could be considered as novel approach for treatment of serious bone injuries which require long term treatment and internal mechanical bone support during healing.
机译:原位成型植入物会非常关注修复严重的骨伤。本研究的目的是制备装有生物活性玻璃纳米粒子和/或盐酸雷诺烯盐(RLX)的新型壳聚糖原位形成植入物(CIFI)。将Raloxifene盐酸盐(RLX)作为选择性雌激素受体调节剂掺入,以利用其抗复苏性能是必不可少的。测试制备的配方,用于它们的体外凝胶化时间,药物释放,可注射性,流变性质,侵蚀率和形态学性质。结果表明,由1%(w / v)壳聚糖组成的制剂,其具有2%(w / v)NaHCO 3和1%(w / v)生物活性玻璃纳米颗粒(Cifi-Bg)具有延伸的最持续的药物释放曲线与缺乏生物活性玻璃纳米颗粒(CIFI)相同的配方相比,4个月具有低爆发释放效果。测试了所选制剂的能力,以提高患者胫骨诱导的刺穿骨再生。结果宣布,与未处理的胫骨穿刺相比,这些制剂能够在12周后提高骨再生,并且含有生物活性玻璃可以被视为治疗严重骨伤的新方法,这些方法需要长期治疗和愈合过程中的内部机械骨支持。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号